Hadassah Medical Center in Jerusalem is the first in the country to join the TriNetX global health research network to increase clinical trial activity and help pharmaceutical companies improve the protocol design and feasibility process.
“I commend this new partnership that will no doubt lead us all to impressive new achievements,” said Prof. Zeev Rotstein, director general of Hadassah Medical Organization.
“The new Hadassah is at the forefront of research, both in Israel and in the international arena,” Rotstein said. “In this way, they improve patients’ chances to benefit from good health and better quality of life.”
Hadassah is a leading hospital complex with two campuses, 1,300 beds, 45 operating theaters and seven intensive care units. Together with The Hebrew University of Jerusalem, it provides education and clinical experience through five schools of medical professions.
The TriNetX cloud-based platform provides on-demand access to clinical data and analytics, enabling researchers to design successful protocols, improve site selection and planning, and create real-world evidence.
“We are excited to have Hadassah Medical Center become part of our growing international presence,” said TriNetX CEO Gadi Lachman. “We believe the added exposure to our pharmaceutical members will prove enormously beneficial for Hadassah.”